Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz
Dr. Reddy’s Laboratories has launched Nivorz, a biosimilar of the immuno-oncology drug nivolumab, in the Indian market. The drug is manufactured in-house and aims to provide a more affordable treatment option for various solid and hematological malignancies.
Why it matters
The introduction of affordable biosimilars is critical for improving patient access to high-cost cancer therapies in emerging markets like India.
Dr. Reddy’s Laboratories on Tuesday said it is foraying into the biosimilar immuno-oncology therapy segment in India with the launch of Nivorz, a biosimilar of Bristol Myers Squibb’s Opdivo (nivolumab).
The biosimilar has been developed and manufactured entirely in-house at its biologics facility in Bachupally, Hyderabad. The launch reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialisation, Dr. Reddy’s said.
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab, it said.
“The launch of Nivorz strengthens our oncology portfolio and expands presence in immuno-oncology. As access to immunotherapy continues to be a challenge for many patients, we remain committed to improving access to high-quality treatment options through affordable biosimilars,” CEO Global Generics M.V. Ramana said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in